What Assort Health Announced About Its Executive Hires and 222 Million Dollars in Funding
Assort Health said on 21 July 2026 that Jon Corn joined as chief revenue officer from Samsara, Kristina Kemp as vice president of customer success from Luma Health and Emil Yeargin as senior vice president of people from Gusto. The company states total funding of 222 million dollars, including a 120 million dollar Series C led by Menlo Ventures, and says its revenue grew 20 times over the previous 15 months. It reports its platform is built on more than 190 million patient interactions, 62,000 care protocols and 1.6 million decision pathways, and cites customer results of a 5 percent lift in appointment volume, a 115 percent increase in labour capacity, up to 4.3 million dollars captured per 100 providers, 97 percent resolution rates and 79 percent referral-to-appointment conversion.
Why the Assort Health Hires Matter to Patient Access Buyers
Hiring a chief revenue officer and a head of people before anything else is the pattern of a company building a sales engine, so expect an attentive sales process and competitive pricing now, and expect upsell pressure later. The customer success hire coming from Luma Health, a competitor in the same group on this site, is the detail worth noting, because it suggests Assort is deliberately buying knowledge of how these deployments go wrong. Twenty times revenue growth off a small base is a sales number, not a performance number.
Where the Assort Health Update Comes From
Assort Health is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
Assort Health original source.
How We Would Research the Assort Health Hires and Funding
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would ask what the customer success team's ratio of staff to accounts is, since that is what a 20 times growth rate usually strains.
- Then we would ask for the referral-to-appointment conversion figure measured at a practice our size rather than across all customers.
- We would fix pricing for the contract term, because a company at this stage of growth has every reason to reprice at renewal.